Young Plasma Transfusion for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Young Plasma Transfusion for Health & Longevity

Created on 08/15/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Young plasma transfusion infuses plasma from a younger donor into an older adult. The use is unapproved. Mouse work shows short-lived tissue changes. Human studies are small safety series in memory and movement disorders. No comparison with enough participants shows it outperforms salt-water for cognition, function, or biological age. Ordinary transfusion harms apply. Not a demonstrated longevity therapy. (Full Review)

Protocol

Additive young plasma (Sha / Stanford / Alkahest)
One unit (~250 mL)
Male-donor plasma from donors aged 18–30; once weekly for four weeks, over 1–2 hours
Denser short course (Parker / Stanford Parkinson)
One unit twice weekly
Four weeks (eight units total); then a four-week observation block
Age
Lower volume and slower rate
Older recipients; volume-overload risk rises with age
Time to effect
Exploratory cognitive scores
Weeks
No validated longevity marker has a known time-to-effect; exploratory scores measured over weeks
Tissue changes in mice
Days
Animal tissue changes appear within days

Benefits

Contraindications
  • IgA deficiency with anti-IgA antibodies (anaphylaxis)
  • Uncontrolled heart failure, including NYHA (New York Heart Association) Class III–IV
  • Recent stroke (any prior stroke)
  • Uncontrolled hypertension or recent uncontrolled atrial fibrillation
  • Active hypercoagulable disorder or full-dose anticoagulation
  • Prior anaphylaxis or severe reaction to any human blood product
  • Pregnancy
  • Active systemic infection or untreated hepatitis B, hepatitis C, or HIV
  • ABO-incompatible plasma unavailable (no matching A/B/O unit)
    •
Key Interactions
  • Anticoagulants (warfarin, apixaban, rivaroxaban, heparin) (absolute caution)
  • ACE inhibitors (lisinopril, enalapril, ramipril) (caution)
  • Recent IVIG (intravenous immunoglobulin) or other human blood products (six-month washout) (caution)
  • Volume expanders and high-salt intake (caution)
  • Aspirin, ibuprofen, and other NSAIDs (monitor)
  • Fish oil, high-dose vitamin E, and other bleeding-prone supplements (monitor)
  • Therapeutic plasma exchange or albumin dilution (caution)
    •

Risk & Side Effects

  • High: Allergic and anaphylactic transfusion reactions; transfusion-associated circulatory overload
    •
  • Medium: Transfusion-related acute lung injury; hemolytic reactions from blood-group–incompatible plasma; residual infectious transmission
    •
  • Low: Febrile nonhemolytic reactions; intraprocedure blood-pressure and heart-rate swings; citrate-related hypocalcemia
    •
  • Speculative: Growth-factor promotion of occult neoplasia
    •

Monitoring

Marker Target Why
ABO/Rh type and screen Compatible unit available Prevents ABO-mismatched plasma
Serum IgA Detectable; not deficient Flags anaphylaxis risk
NT-proBNP Track vs own baseline; conventional often <125 pg/mL Volume-overload risk
Blood pressure Individual baseline; not uncontrolled hypertension Intraprocedure swings
CMP Creatinine stable vs baseline; ionized calcium in lab range Kidney reserve and citrate binding
CBC Hemoglobin and platelets stable vs baseline Hemodilution, unexpected cytopenias

Cadence: During each infusion, at 24 hours, at the end of a four-week block, then at about four weeks after the last unit

Qualitative Assessment

  • New breathlessness, orthopnea (breathlessness lying flat), or ankle swelling in the 24 hours after a unit
  • Word-finding and afternoon mental stamina across a four-week block
  • Sleep quality the night of infusion
  • Flushing, hives, or throat tightness during the infusion
  • Tingling around the mouth or muscle cramp (citrate)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.